GPT and Cirrhosis: According to current guidance, therapy in HBeAg negative hepatitis is recommended in patients with elevated ALT ≥ 2 × upper limit of normal (ULN) and HBV DNA ≥ 2000 IU/mL and in cirrhosis irrespective of ALT [76].